Cisplatin vs Carboplatin: Only Two Comparisons Reach High-Certainty Evidence
This umbrella meta-analysis grades the certainty of evidence for cisplatin versus carboplatin across seven solid tumor types, showing where platinum selection is evidence-based and where it rests on weak data.
📅 Journal publication: Sep 1, 2026·Last updated: Nov 5, 2026
Cisplatin outperforms carboplatin in certain cancers but with higher toxicity.
The study clarifies the comparative efficacy and safety of cisplatin and carboplatin across several solid tumor types. Cisplatin shows higher response rates in urothelial and cervical cancer, but also higher ototoxicity and nephrotoxicity. No survival differences in most cancers. The data is high-certainty for some cancers but overall shows moderate to low-certainty evidence, restricting definitive conclusions on survival benefits. Cisplatin is more effective in specific cancers but with higher toxicity risk.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Jiménez-Labaig P, Mirallas O, Pereira F, Sanz J, Felip E, Rodon J, Colombo N, Galsky MD, Harrington KJ
Citation:Jiménez-Labaig P, Mirallas O, Pereira F, et al. Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors: An Umbrella Meta-Analysis. JAMA network open. 2026;9(9):e2634287. doi:10.1001/jamanetworkopen.2026.34287